BRD9 degrader CFT8634

{
  "id": "MLC-T-ONC-012107",
  "term": "BRD9 degrader CFT8634",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable heterobifunctional protein degrader of bromodomain-containing protein 9 (BRD9; sarcoma antigen NY-SAR-29; rhabdomyosarcoma antigen MU-RMS-40.8), with potential antineoplastic activity. CFT8634 is comprised of an E3 ligase-binding moiety and a BRD9-binding moiety. Upon oral administration, BRD9 degrader CFT8634 targets and binds to BRD9 with its BRD9-binding moiety. Upon BRD9 binding, the E3 ligase-binding moiety binds to cereblon (CRBN), a component of the CRL4-CRBN E3 ubiquitin ligase complex, which directs proteins for destruction, resulting in the proteasome-mediated degradation of BRD9. This leads to an inhibition of the growth of tumor cells that rely on BRD9 for survival. BRD9, a component of one form of the Brg/Brahma-Associated Factor (BAF) complex, is needed for the survival of certain cancer cells due to mutations.",
  "synonyms": [
    "BRD9-targeting protein degrader CFT8634",
    "BiDAC degrader CFT8634",
    "BRD9 protein degrader CFT8634",
    "bifunctional degradation activating compound CFT8634"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/brd9-degrader-cft8634/"
}